Cognition Therapeutics received grant support from the NIH segment on July 12, 2025, for a clinical study.
2 reports, 1 independent
Updated Jul 12
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cognition Therapeutics received grant support from the NIH segment on July 12, 2025, for a clinical study.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Cognition Therapeutics (United States)
company in Pittsburgh, United States
Nothing else this week.
-
National Institutes of Health
government organization in Shah Alam, Malaysia
Related events
- The National Institutes of Health (NIH) has awarded a five-year, $4.5 million grant to MaineHealth for a follow-up study.
- A clinical study led by Dr. Swee Lay Thein is underway at the National Institutes of Health and is subject to oversight by the Food and Drug Administration.
- NIH cuts budgets and personnel, impacting funded research leading to FDA-approved treatments.
- NIH data informs market need for a device that requires FDA clearance to achieve Medicare coverage.
- The National Institutes of Health requires increased federal budget funding, with research demonstrating a potential $2.50 return on investment, discussed alongside U.S. Senator McCormick.
Coverage
Newest first; wire copies grouped- Insider MonkeyCognition Therapeutics, Inc. (CGTX) Retains Buy Rating on START Study Progress Cognition Therapeutics, Inc. (NASDAQ:CGTX) is among the fundamentally strong penny stocks to invest in. H.C. Wainwright
- Unknown outlet